HOME >> BIOLOGY >> NEWS
May: Multiple Sclerosis Awareness Month -- latest research is good news

Montreal, QC -- May is Multiple Sclerosis Month and there is no better way of raising awareness for this unpredictable and often debilitating disease then by highlighting the latest research that might offer hope for the 55 to 75, 000 sufferers across Canada. A new drug under investigation for Multiple Sclerosis (MS) appears to be safe and effective according to studies involving researchers at the Montreal Neurological Institute. The studies, presented this week at the American Academy of Neurologys (AAN) 59th Annual Meeting in Boston, also provide deeper insight into the biology of this complex disease. Canadians have one of the highest rates of Multiple Sclerosis (MS) in the world with approximately 1,000 new cases of MS diagnosed each year. MS is the most common neurological disease affecting young adults in Canada and affects 18% of all Quebecers.

The Phase I and Phase II studies involved people in Canada and the USA with relapsing-remitting MS, in which symptoms flare up and then subside. Treatment with the drug rituximab significantly reduced the number of new brain lesions and the frequency of relapses, times when symptoms of MS flare up.

Rituximab is a therapeutic antibody that selectively targets and depletes a set of immune cells called B-cells by binding to a specific protein on their surface.

"This is the first drug to selectively target B-cells in MS and the significance of its effectiveness is two-fold," says Dr. Amit Bar-Or, neurologist at the Montreal Neurological Institute (MNI) at McGill University, Montreal, Canada and lead investigator in the Phase I study. "Not only might it present a significantly improved therapy for patients with relapsing-remitting MS, but it provides a clearer picture of the role that B-cells play in the disease. Its a particularly exciting time and we think meaningful to advancing treatment options for patients."

The Phase I trial was primarily designed to assess the safety
'"/>

Contact: Anita Kar
anita.kar@mcgill.ca
514-398-3376
Montreal Neurological Institute and Hospital
2-May-2007


Page: 1 2

Related biology news :

1. Alleviating the burden of Multiple Sclerosis
2. Multiple sclerosis progression linked to immune-cell substance
3. Multiple genes permit closely related fish species to mix and match their color vision
4. Multiple genetic flavors may explain autism
5. Multiple sightings of long-lost woodpecker reported
6. Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia
7. Brain Awareness Week teaches kids how their brains work
8. Breast Cancer Month story tips from Georgetown University Medical Center
9. National Academies advisory: Feb. 15 program for African-American History Month
10. AAAS decries latest stem cell veto
11. Brain, size and gender surprises in latest fossil tying humans, apes and monkeys

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... March 23, 2017 The report "Gesture Recognition and Touchless ... and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is ... of 29.63% between 2017 and 2022. Continue Reading ... ... ...
(Date:3/20/2017)... , March 20, 2017 At this year,s ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand ... is this year,s CeBIT partner country. At the largest German biometrics ... in use: fingerprint, face and iris recognition as well as DERMALOGĀ“s multi-biometrics ... ...
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, ... Simple," and 23andMe , the leading personal genetics ... choices.  Zipongo can now provide customers with personalized nutrition ... goals and biometrics, but also genetic markers impacting how ... Zipongo,s personalized food decision support platform uses biometrics ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... 23, 2017 In today,s pre-market ... in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), ... MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." ... report at: ...
(Date:3/22/2017)... ... March 22, 2017 , ... Researchers ... from small lab samples to full-size tissues, bones, even whole organs to implant ... system that delivers blood deep into the developing tissue. , Current bioengineering ...
(Date:3/22/2017)... -- Good Start Genetics, a leading family genomics company, ... covered lives mark through its most recent payor addition, ... . With newly signed contracts nationally and others in ... acceptance based on the quality of its science, the ... industry-leading customer care and support and its published cost-effectiveness ...
(Date:3/22/2017)... The global chronic kidney disease ... by Transparency Market Research (TMR). The top four players, ... Inc., accounted for a share of only 41.4% in ... market are focusing aggressively on mergers, acquisitions, and strategic ... to lead to market consolidation in the next few ...
Breaking Biology Technology:
Cached News: